Sareum Holdings (SAR) , a clinical-stage biotechnology company, has received a Notice of Allowance from the Japan Patent Office for its leading drug SDC-1801, a TYK2/JAK1 kinase inhibitor, securing its medical applications in treating immune disorders.
This Japanese patent, alongside the recent approval in China, safeguards SDC-1801 and its medical applications in treating inflammatory or immune disorders.
Patent applications in Europe, the US, and other regions are under review, with expectations of imminent approval pending formalities.
Dr John Reader, Sareum's Chief Scientific Officer, commented: "The recent Notice of Allowance from the Japan Patent Office bolsters our growing confidence in SDC-1801, our lead TYK2/JAK1 kinase inhibitor. Our Phase 1a clinical trial in Australia is progressing well, and this latest patent recognition in Japan supports our intellectual property around this programme."
View from Vox
Sareum Holdings is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer. The company focuses on targeting small molecule therapeutics, which are designed to disrupt the biochemical processes that drive the growth of cancers and development of auto-immune diseases.
Its lead programme SDC-1801 is well placed in a rapidly growing market. Psoriasis is an autoimmune dermatological condition affecting more than 125 million adults worldwide, with a market size for potential treatments estimated at US$27 billion. Sareum believes that TYK2/JAK1 inhibition offers the potential for increased efficacy in psoriasis, compared with existing approved therapies.
Looking forward, Sareum said that continued progress of its Phase 1a trial and its supporting preclinical work, combined with growing commercial and scientific momentum building around the TYK2/JAK1 class, underpins confidence around the commercial potential for this molecule.
Follow Sareum Holdings for more News and Updates: